The EUbOPEN consortium (Enabling and Unlocking Biology in the OPEN) aims to generate a comprehensive pharmacological drug library and make it accessible to the research community. The EU project of the Innovative Medicines Initiative (IMI2), which is funded for 5 years, is a collaboration of 22 institutions and pharmaceutical companies. At GSH, active ingredients are to be tested in patient-derived assays.
Langener Science Award for Prof. Dr. Krause for research on the bone marrow microenvironment
Friday, Nov 15, 2019, Prof. Dr. Daniela Krause received the Langener Wissenschaftspreis at the Paul-Ehrlich-Institut for her work on “Home is where the bone is – The bone marrow as an innovative therapeutic approach to blood formation”. The Award was presented by Ministerialdirigent Dr. Lars-Christoph Nickel, Federal Ministry of Health (BMG). “The Langener Wissenschaftspreis honors researchers who have dedicated themselves with great dedication to medical progress,” said Dr. Nickel. “We are pleased to honour Prof. Daniela Krause, a scientist who is researching innovative therapeutic approaches and is instrumental in preparing for their rapid testing in clinical trials,” added Prof. Klaus Cichutek, President of the Paul Ehrlich Institute (PEI), Federal Institute for Vaccines and Biomedical Drugs. “I feel very honored and gratefully accept the award on behalf of our entire research group. Every new therapeutic strategy is accompanied by doubts and regression. This Award, especially from the Paul Ehrlich Institute, is so important because it seems to show us that we are on the right track,” says Prof. Daniela Krause.